30.92
0.19%
+0.06
After Hours:
30.99
0.07
+0.23%
BridgeBio Pharma Inc stock is currently priced at $30.92, with a 24-hour trading volume of 2.00M.
It has seen a +0.19% increased in the last 24 hours and a -12.38% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $30.57 pivot point. If it approaches the $31.52 resistance level, significant changes may occur.
BridgeBio Pharma Inc Stock (BBIO) Financials Data
BridgeBio Pharma Inc (BBIO) Revenue 2023
BBIO reported a revenue (TTM) of $9.30 million for the quarter ending December 31, 2023, a -88.02% decline year-over-year.
BridgeBio Pharma Inc (BBIO) Net Income 2023
BBIO net income (TTM) was -$643.20 million for the quarter ending December 31, 2023, a -33.67% decrease year-over-year.
BridgeBio Pharma Inc (BBIO) Cash Flow 2023
BBIO recorded a free cash flow (TTM) of -$529.03 million for the quarter ending December 31, 2023, a -24.24% decrease year-over-year.
BridgeBio Pharma Inc (BBIO) Earnings per Share 2023
BBIO earnings per share (TTM) was -$3.94 for the quarter ending December 31, 2023, a -20.49% decline year-over-year.
BridgeBio Pharma Inc Stock (BBIO) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Scott Randal W. | Director |
Mar 01 '24 |
Sale |
34.00 |
2,500 |
85,000 |
6,500 |
Valantine Hannah | Director |
Feb 15 '24 |
Option Exercise |
8.45 |
2,915 |
24,632 |
4,679 |
Valantine Hannah | Director |
Feb 15 '24 |
Sale |
37.75 |
2,915 |
110,041 |
1,764 |
Valantine Hannah | Director |
Jan 16 '24 |
Option Exercise |
8.45 |
2,915 |
24,632 |
4,679 |
Valantine Hannah | Director |
Jan 16 '24 |
Sale |
37.97 |
2,915 |
110,683 |
1,764 |
MCCORMICK FRANK | Director |
Dec 26 '23 |
Sale |
42.06 |
100,000 |
4,206,000 |
627,689 |
Scott Randal W. | Director |
Dec 18 '23 |
Sale |
40.00 |
2,000 |
80,000 |
9,000 |
Valantine Hannah | Director |
Dec 15 '23 |
Option Exercise |
8.45 |
2,915 |
24,632 |
4,679 |
Valantine Hannah | Director |
Dec 15 '23 |
Sale |
36.12 |
2,915 |
105,290 |
1,764 |
Scott Randal W. | Director |
Dec 01 '23 |
Sale |
29.40 |
2,500 |
73,500 |
11,000 |
BridgeBio Pharma Inc Stock (BBIO) Latest News
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
Zacks Investment Research
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
GlobeNewswire Inc.
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
Zacks Investment Research
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
GlobeNewswire Inc.
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
GlobeNewswire Inc.
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc. finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology. Its principal products in development programs include BBP-265, an oral small molecule transthyretin (TTR) for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers, as well as for the treatment of achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company was founded in 2015 and is headquartered in Palo Alto, California.
Cap:
|
Volume (24h):